Skip to content

New Cases of EoE in Children in Poland.

Register of New Diagnoses of Eosinophilic Esophagitis in Children in Poland.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07772388
Enrollment
250
Registered
2026-08-19
Start date
2024-06-01
Completion date
2026-05-31
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic Disease, Eosinophilic Disorder, Eosinophilic Esophagitis (EoE), Gastroenterology, Pediatric

Keywords

eosinophilic esophagitis, incidence of EoE, EoE, pediatric EoE

Brief summary

The aim of the study is to assess the incidence of EZP in Poland in the pediatric population and characteristics of Polish patients with EZP, i.e. their demographic, clinical, endoscopic and histological features. Another important objective of the study is to identify areas where the diagnosis and treatment of EZP in children can be improved. The study is prospective and non-interventional.

Detailed description

Data will be collected in the REDCap (Research Electronic Data Capture) platform, which ensures the security of collected data and widely used in international clinical trials. All centers performing endoscopic examinations in children in Poland will be invited to participate in the study. One person from each center will be designated to collect data and update the database. The data entered will be regularly updated with the results of follow-up examinations and the effects of treatment of patients by a designated person at the center. The data entered will only include data collected during routine clinical practice. The registry will not contain any data enabling the identification of patients, e.g., home address. Inclusion of data in the registry will not pose any health risks and does not require any tests other than routine ones. Participation in the registry is voluntary and requires the written consent of the parent/legal guardian and/or patient. Participation may be refused without giving a reason, without affecting the patient's treatment. Consent may be changed or withdrawn at any time. The attending physician will inform the patient and parent/legal guardian about the database and explain its value and benefits as well as the rights of participants. In addition, each participant will be provided with an information brochure about the registry.

Interventions

OTHERData collection

Patient data will include information collected during routine clinical practice, e.g., body weight, height, EZP symptoms, allergy symptoms, laboratory test results, endoscopy results, etc. Entering data into the registry will not pose any health risks and does not require any tests beyond routine ones.

Sponsors

Medical University of Warsaw
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* age \< 18 years, * diagnosis of EZP based on medical history and histopathological examination of esophageal biopsies taken during gastroscopy (≥15 eosinophils/field of view in ≥1 biopsy), * consent of legal guardians and the child (in the case of patients ≥12 years of age) to participate in the study.

Exclusion criteria

* age \> 18 years, * inability of parents or guardians to give informed consent, * patients who did not consent to participate in the study (applies to patients \> 12 years of age), * congenital defects of the gastrointestinal tract, * status after surgery for gastrointestinal cancer.

Design outcomes

Primary

MeasureTime frameDescription
Characteristics of Polish pediatric patientsJune 2024 - May 2026Characteristics of Polish patients with EZP, f.e., their demographic, clinical, endoscopic and histological features.
Incidence of EoE in children in Poland.June 2024 - May 2026Assessment of the incidence of EZP in Poland in the pediatric population.

Secondary

MeasureTime frameDescription
Improving the efficiency of proposed diagnostic and therapeutic protocolsJune 2024 - May 2026Identification of areas where the diagnosis and treatment of EZP in children can be improved.

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026